{"Clinical Trial ID": "NCT00777101", "Intervention": ["INTERVENTION 1:", "Neratinib", "Neratinib", "Neratinib: Tablets, 240 mg once daily until disease progression or unacceptable toxicity", "INTERVENTION 2:", "- Lapatinib+Capecitabine", "- Lapatinib plus Capecitabine", "Lapatinib: Tablets 1250mg once daily until disease progression or unacceptable toxicity.", "Capecitabine: Tablets 2000mg/m2 administered in two uniformly distributed daily doses for the first 14 days of each 21-day cycle."], "Eligibility": ["Incorporation criteria:", "Stage IIIB, IIIC or IV erbB2 (HER2) positive breast cancer", "Prior use of Herceptin (trastuzumab) and a taxane", "Adequate cardiac and renal function", "- Exclusion criteria:", "More than 2 previous treatments for Herceptin (trastuzumab) or previous use of Xeloda (capecitabine) and/or Tykerb (lapatinib) [Tyverbe]", "Bone is the only site of the disease", "Metastasis of the active central nervous system (the subjects should be stable and not anticonvulsant and steroid)", "A significant gastrointestinal disorder with diarrhoea as a major symptom"], "Results": ["Performance measures:", "\u00b7 Progression Free Survival", "The time interval between the date of randomization and the earliest date of progression by criterion of response assessment in solid tumour criteria (RECIST) or death due to any cause. For subjects without death or progression, censorship was at the last valid tumour assessment.", "Time limit: From randomization date to progression or death, estimated up to 69 months", "Results 1:", "Title of the arm/group: Neratinib", "Description of the arm/group: Neratinib", "Neratinib: Tablets, 240 mg once daily until disease progression or unacceptable toxicity", "Total number of participants analysed: 117", "Median (95% confidence interval)", "Unit of measure: months 4.53 (3.12 to 5.65)", "Results 2:", "Title of the arm/group: Lapatinib+Capecitabine", "Description of the arm/group: Lapatinib plus Capecitabine", "Lapatinib: Tablets 1250mg once daily until disease progression or unacceptable toxicity.", "Capecitabine: Tablets 2000mg/m2 administered in two uniformly distributed daily doses for the first 14 days of each 21-day cycle.", "Total number of participants analysed: 116", "Median (95% confidence interval)", "Unit of measure: months 6.83 (5.85 to 8.21)"], "Adverse Events": ["Undesirable Events 1:", "Total: 31/116 (26.72%)", "Neutropenia 1/116 (0.86%)", "Thrombocytopenia 1/116 (0.86%)", "Acute myocardial infarction 1/116 (0.86%)", "Myocardial infarction 0/116 (0.00 %)", "Pericardial infusion 0.116 (0.00 %)", "Abdominal pain 3/116 (2.59 per cent)", "Ascites 1/116 (0.86%)", "Diarrhoea 3/116 (2.59%)", "Gingival haemorrhage 1/116 (0.86%)", "Intestinal haemorrhage 1/116 (0.86%)", "Nausea 2/116 (1.72%)", "Adverse Events 2:", "Total: 24/115 (20.87 per cent)", "Neutropenia 1/115 (0.87%)", "Thrombocytopenia 0/115 (0.00 %)", "Acute myocardial infarction 0/115 (0.00 %)", "Myocardial infarction 1/115 (0.87%)", "1/115 (0.87%)", "Abdominal pain 0/115 (0.00 %)", "Ascites 0/115 (0.00 %)", "Diarrhoea 4/115 (3.48%)", "Gingival haemorrhage 0/115 (0.00 %)", "Intestinal haemorrhage 0/115 (0.00 %)", "Nausea 3/115 (2.61 per cent)"]}